The 2017 Hormone Therapy Position Statement of The North American Menopause Society

The North American Menopause Society 2017 Hormone Therapy Position Statement Advisory Panel

Disclosures

The North American Menopause Society (NAMS). 2018;24(7):728-753. 

In This Article

Hormone Therapy and Quality of Life

Women who are severely symptomatic at baseline in clinical trials show a significant improvement in health-related QOL and menopause-specific QOL with HT when validated QOL measurement instruments are used, whereas no significant improvement is seen in women without severe symptoms at baseline.[116]

Key Points

  • The effect of severe menopause symptoms on QOL may be substantial.

  • Desire for improved QOL may cause women and providers to accept a greater degree of risk to obtain significant improvement.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....